Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Market Access
  • Deal finally unlocks NHS access to ITF’s Duchenne drug
  • Market Access

Deal finally unlocks NHS access to ITF’s Duchenne drug

Pharmaphorum

After nearly two years of wrangling, ITF's Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.

Rare Disease

Read full story

pharminent May 11, 2026 (Last updated: May 11, 2026)

Pharmaphorum

After nearly two years of wrangling, ITF’s Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.

Rare Disease

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: BMS’ Sotyktu secures EC approval for psoriatic arthritis
Next: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher

Related Stories

  • Market Access

GSK’s Nucala secures NICE COPD endorsement

pharminent May 29, 2026
  • Market Access

Medicare Advantage Out-of-Pocket Limits: Variation and Trends

pharminent May 28, 2026
  • Market Access

France ‘first EU country to cover obesity drugs’

pharminent May 28, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.